X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the raise will advance Anellogy™ platform toward the clinic, transforming commensal anelloviruses into life-saving therapies, creating next-generation programable genetic medicines.
Lead Product(s): Anellovirus-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexandria Venture Investments
Deal Size: $86.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 09, 2023
Details:
Ring’s conception of Anellovectors™ as a broad bioplatform that could be applicable across diseases holds tremendous promise for unlocking the field of genetic medicines.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Data from poster presentation will illustrate that most anellovirus peptides are not associated with an antibody response in humans when compared to other known human viruses.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
